A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of JDTic

Neuropsychopharmacology

Volumn 40, Issue 9, 2015, Pages 2059-2065

  Buda, Jeffrey J ^a   Carroll, F I ^b   Kosten, Thomas R ^c   Swearingen, Dennis ^d   Walters, Bradford B ^b  

^a RTI HEALTH SOLUTIONS   (United States)

^b RTI INTERNATIONAL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d CELERION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JDTIC; KAPPA OPIATE RECEPTOR ANTAGONIST; PLACEBO; UNCLASSIFIED DRUG; 7-HYDROXY-N-(1-((4-(3-HYDROXYPHENYL)-3,4-DIMETHYL-1-PIPERIDINYL)METHYL)-2-METHYLPROPYL)-1,2,3,4-TETRAHYDRO-3-ISOQUINOLINECARBOXAMIDE; KAPPA OPIATE RECEPTOR; PIPERIDINE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ADULT; ADVERSE OUTCOME; ANTICOAGULATION; ARTICLE; ASYMPTOMATIC DISEASE; BRADYCARDIA; CARDIOVASCULAR EFFECT; CLINICAL ASSESSMENT; CLINICAL CHEMISTRY; CLINICAL EVALUATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HEMODYNAMIC MONITORING; HUMAN; HUMAN EXPERIMENT; LIMIT OF QUANTITATION; MALE; NONSUSTAINED VENTRICULAR TACHYCARDIA; NORMAL HUMAN; ORTHOPEDIC FIXATION DEVICE; ORTHOSTATIC BLOOD PRESSURE; POSITIONAL DIZZINESS; PRIORITY JOURNAL; PROFILE OF MOOD STATES; PSYCHOMOTOR ACTIVITY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SINGLE DRUG DOSE; TELEMETRY; TIME TO TREATMENT; URINALYSIS; VITAL SIGN; WAYNE SACCADIC FIXATOR; ADOLESCENT; ANTAGONISTS AND INHIBITORS; AREA UNDER THE CURVE; BLOOD; CHEMICALLY INDUCED; COHORT ANALYSIS; DIET RESTRICTION; DOSE RESPONSE; ELECTROCARDIOGRAPHY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TIME FACTOR; URINE; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AREA UNDER CURVE; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FASTING; HUMANS; MALE; MIDDLE AGED; PIPERIDINES; RECEPTORS, OPIOID, KAPPA; TACHYCARDIA, VENTRICULAR; TETRAHYDROISOQUINOLINES; TIME FACTORS; YOUNG ADULT;

EID: 84937163102     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2015.27     Document Type: Article

References (39)

1. Ationu A, Sorensen K, Whitehead B, Singer D, Carter N (1993). Ventricular expression and circulating levels of immunoreactive dynorphin in heart transplant recipients. Clin Sci (Lond) 85: 1-4.
2. Bian JS, Zhang WM, Xia Q, Wong TM (1998). Phospholipase C inhibitors attenuate arrhythmias induced by kappa-receptor stimulation in the isolated rat heart. J Mol Cell Cardiol 30: 2103-2110.
3. Bjerregaard P (1982). Premature beats in healthy subjects 40-79 years of age. Eur Heart J 3: 493-503.
4. Brodsky M, Wu D, Denes P, Kanakis C, Rosen KM (1977). Arrhythmias documented by 24 hour continuous electrocardio-graphic monitoring in 50 male medical students without apparent heart disease. Am J Cardiol 39: 390-395.
5. Bruchas MR, Chavkin C (2010). Kinase cascades and ligand-directed signaling at the kappa opioid receptor. Psychopharma-col 210: 137-147.
6. Bruchas MR, Yang T, Schreiber S, DeFino M, Kwan SC, Li S et al (2007). Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-jun N-terminal kinase. J Biol Chem 282: 29803-29811.
7. Carroll FI, Carlezon WA Jr (2013). Development of k opioid receptor antagonists. J Med Chem 56: 2178-2195.
8. Carroll FI, Dolle RE (2014). The discovery and development of the N-substituted trans-3, 4-dimethyl-4-(3'-hydroxyphenyl)piperi-dine class of pure opioid receptor antagonists. Chem Med Chem 9: 1638-1654.
9. Clarke JM, Hamer J, Shelton JR, Taylor S, Venning GR (1976). The rhythm of the normal human heart. Lancet 1: 508-512.
10. Coles JA Jr, Sigg DC, Iaizzo PA (2003). Role of kappa-opioid receptor activation in pharmacological preconditioning of swine. Am J Physiol Heart Circ Physiol 284: H2091-H2099.
11. Drosatos K, Drosatos-Tampakaki Z, Khan R, Homma S, Schulze PC, Zannis VI et al (2011). Inhibition of c-jun-N-terminal kinase increases cardiac peroxisome proliferator-activated receptor alpha expression and fatty acid oxidation and prevents lipopo-lysaccharide-induced heart dysfunction. J Biol Chem 286: 36331-36339.
12. Guo L, Abrams RM, Babiarz JE, Cohen JD, Kameoka S, Sanders MJ et al (2011). Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyo-cytes. Toxicol Sci 123: 281-289.
13. Hartlage MAG, Theisen MM, de Oliveira NPM, Aken HV, Fobker M, Weber TP (2006). Kappa-opioid receptor antagonism improves recovery from myocardial stunning in chronically instrumented dogs. Anesth Analg 103: 822-832.
14. Hinkle LE, Carver ST, Stevens M (1969). The frequency of asymptomatic disturbances of cardiac rhythm and conduction in middle-aged men. Am J Cardiol 24: 629-650.
15. Hospira (2007). Package insert for Naloxone Hydrochloride Injection, USP. EN-1367. Hospira: Lake Forest, IL, USA.
16. Hunter R (2005). Ventricular tachycardia following naloxone administration in an illicit drug misuse. J Clin Forensic Med 12: 218-219.
17. Jaiswal A, Kumar S, Seth S, Dinda AK, Maulik SK (2010). Effect of U50, 488H, a k-opioid receptor agonist on myocardial a-and b-myosin heavy chain expression and oxidative stress associated with isoproterenol-induced cardiac hypertrophy in rat. Mol Cell Biochem 345: 213-240.
18. Jin-Cheng L, Wen Y, Zhao Y, Quan-Yu Z, Shu-Miao Z, Hai-Tao G et al (2008). Anti-arrhythmic effects of kappa-opioid receptor and its changes in ischemia and reperfusion. Arch Med Res 39: 483-488.
19. Lendeckel U, Muller C, Rocken C, Laube B, Tager M, Huth C et al (2005). Expression of opioid receptor subtypes and their ligands in fibrillating human atria. Pacing Clin Electrophysiol 28(Suppl 1): S275-S279.
20. Lishmanov AY, Maslov LN, Lasukova TV, Crawford D, Wong TM (2007). Activation of kappa-opioid receptor as a method for prevention of ischemic and reperfusion arrhythmias: role of protein kinase C and K(ATP) channels. Bull Exp Biol Med 143: 187-190.
21. Liu L, Hu D, Pan X, Lu R, Dan F (2005). Subclass opioid receptors associated with the cardiovascular depression after traumatic shock and the antishock effects of its specific receptor antagonists. Shock 24: 470-475.
22. Llobell F, Laorden ML (1995). Characterization of the opioid receptor subtypes mediating the negative inotropic effects of DAMGO, DPDPE and U-50, 488H in isolated human right atria strips. Neuropeptides 29: 115-119.
23. Lowe SL, Wong CJ, Witcher J, Gonzales CR, Dickinson GL, Bell RL et al (2014). Safety, tolerability, and pharmacokinetic evaluation of single-and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects. Pharmacokinetics 54: 968-978.
24. Macallum GE, Houston BJ (1993). Characterization of cardiac alterations in nonsedated cynomolgus monkeys. Am J Vet Res 54: 327-332.
25. Melief EJ, Miyatake M, Carroll FI, Béguin C, Carlezon WA, Cohen BM et al (2011). Duration of action of a broad range of selective k-opioid receptor antagonists is positively correlated with c-jun N-terminal kinase-1 activation. Mol Pharmacol 80: 920-929.
26. Min SS, Turner JR, Nada A, DiMino TL, Hynie I, Kleiman R et al (2010). Evaluation of ventricular arrhythmias in early clinical pharmacology trials and potential consequences for later development. Am Heart J 159: 716-729.
27. Peart JN, Gross ER, Gross GJ (2004). Effect of exogenous kappa-opioid receptor activation in rat model of myocardial infarction. J Cardiovasc Pharmacol 43: 410-415.
28. Peng J, Sarkar S, Chang SL (2012). Opioid receptor expression in human brain and peripheral tissues using absolute quantitative real-time RT-PCR. Drug Alcohol Depend 124: 223-228.
29. Pyle WG, Lester JW, Hofmann PA (2001). Effects of kappa-opioid receptor activation on myocardium. Am J Physiol Heart Circ Physiol 281: H669-H678.
30. Sobanski P, Krajnik M, Shaqura M, Bloch-Boguslawska E, Schäfer M, Mousa SA (2014). The presence of mu-, delta-, and kappa-opioid receptors in human heart tissue. Heart Vessels 29: 855-863.
31. Surendra H, Diaz RJ, Harvey K, Tropak M, Callahan J, Hinek A et al (2013). Interaction of d and k opioid receptors with adenosine A1 receptors mediates cardioprotection by remote ischemic preconditioning. J Mol Cell Cardiol 60: 142-150.
32. Thomas JB, Atkinson RN, Vinson NA, Catanzaro JL, Perretta CL, Fix SE et al (2003). Identification of (3R)-7-hydroxy-N-((1S)-1-{[(3R, 4R)-4-(3-hydroxyphenyl)-3, 4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1, 2, 3, 4-tetrahydro-3-isoquinolinecarboxamide as a novel and potent and selective opioid k receptor antagonist. J Med Chem 46: 3127-3137.
33. Tomai F, Crea F, Gaspardone A, Versaci F, Ghini AS, Ferri C et al (1999). Effects of naloxone on myocardial ischemic preconditioning in humans. J Am Col Cardiol 33: 1863-1869.
34. Ventura C, Spurgeon H, Lakatta EG, Guarnieri C, Capogrossi MC (1992). Kappa and delta opioid receptor stimulation affects cardiac myocytes function and Ca2 + release from an intra-cellular pool in myocytes and neurons. Circ Res 7: 66-81.
35. Xiao GS, Zhou JJ, Cheung YF, Li GR, Wong TM (2003). Effects of U50, 488H on transient outward and ultra-rapid delayed rectifier K+ currents in young human atrial myocytes. Eur J Pharmacol 473: 97-103.
36. Xiu J, Liu J, Li H, Fu L, Ding D, Han D (2013). The effects of kappa-opioid receptor on stretch-induced electrophysiological changes in infarcted rat hearts. Am J Med Sci 345: 129-135.
37. Yu XC, Wang HX, Pei JM, Wong TM (1999). Anti-arrhythmic effect of kappa-opioid receptor stimulation in the perfused rat heart: involvement of a cAMP-dependent pathway. J Mol Cell Cardiol 31: 1809-1819.
38. Zatta AJ, Kin H, Yoshishige D, Jiang R, Wang N, Reeves JG et al (2008). Evidence that cardioprotection by postconditioning involves preservation of myocardial opioid content and selective opioid receptor activation. Am J Physiol Heart Circ Physiol 294: H1444-H1451.
39. Zhou JJ, Pei JM, Wang GY, Wu S, Wang WP, Cho CH et al (2001). Inducible HSP70 mediates delayed cardioprotection in rat ventricular myocytes. Am J Physiol Heart Circ Physiol 281: H40-H47.